Forecasts show the obesity and diabetes drugs market expanding through 2035 on GLP-1 adoption, Europe's HIFU market reaching USD 65.57B by 2033, and AI precision medicine growing at a 31.3% CAGR.
A study in Diabetologia shows type 2 diabetes in lean Africans is driven by insulin shortage, not insulin resistance, and may require different treatment than standard guidelines. The study analyzed data from over 3,300 African adults and found distinct complication patterns between lean and overweight patients.
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
Semaglutide may lower risks of adult-onset seizures and alcohol-related hospitalizations, new studies find. Brazil approved five semaglutide injectables, and a commentary updates obesity care with GLP-1 drugs.
Rosalind Franklin University secured a $3.4 million military health grant, doubled its Helix 51 incubator space, and brought a clinical trial organization to its Innovation and Research Park. The developments strengthen the region’s bioscience hub and fill a gap in Phase I clinical trial capacity in Illinois.
Novartis beat second-quarter profit expectations as Kisqali, Kesimpta and Leqvio offset a 50% plunge in Entresto sales. The Swiss drugmaker maintained its full-year guidance and awaits late-stage data on three experimental drugs.
Eli Lilly will file its triple-agonist obesity drug retatrutide in early 2027 via a Biologics License Application, seeking stronger market protections. Positive Phase 3 results showed up to 22.6% weight loss, while cardiovascular safety data raised some questions.
The Supreme Court will hear Hikma's appeal in the 'skinny label' patent fight over Amarin's Vascepa. The ruling could affect generic drug competition and investment in new drug indications.
Semaglutide improves kidney, survival, and quality-of-life outcomes in type 2 diabetes with CKD, per FLOW trial analyses. Benefits were consistent across cardiovascular and severity subgroups, adding eight full-health days per year.
Novartis posted Q2 2026 earnings above expectations but a 50% drop in Entresto sales from U.S. generics hurt performance. The company highlighted new EU and Japan approvals for Rhapsido and Itvisma, and a manufacturing restructuring including a German plant closure and investment in radioligand production. A $1.8 billion peptide drug pact with Unnatural Products was also announced.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07783802 |
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event |
NOT_YET_RECRUITING | PHASE2 |
| NCT07780552 |
CHIP in Health and Disease |
NOT_YET_RECRUITING | |
| NCT07769190 |
Cardiovascular Mortality Prediction in Maintenance Hemodialysis Patients |
COMPLETED | |
| NCT07748858 |
Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities |
RECRUITING | |
| NCT07738250 |
Routine LDL Exam For Cancer Survivors |
COMPLETED | |
| NCT07730385 |
Fish Oil and HDL Function in Patients on Maintenance Hemodialysis |
NOT_YET_RECRUITING | NA |
| NCT07721428 |
Salivary Angiotensin-Converting Enzyme and Periodontal Disease in Cardiovascular Disease |
COMPLETED | |
| NCT07712380 |
A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events |
NOT_YET_RECRUITING | PHASE2 |
| NCT07681180 |
Evaluation of Anxiety Reduction in the Cathlab by Means of Pharmacological and Non-pharmacological Strategies |
NOT_YET_RECRUITING | NA |
| NCT07678606 |
Association Between 4D MRI Parameters and the Clinical Characteristics and Prognosis of Major Chronic Diseases |
NOT_YET_RECRUITING |
